EpiPen Marketing Approval Transferred to Pfizer from Mylan

Pfizer Japan announced on October 30 that the marketing approval for EpiPen Injection 0.15 mg/0.3 mg (adrenaline), an adjunctive treatment of anaphylaxis, will be transferred from Mylan Seiyaku to Pfizer Japan on November 1. From November 1 onward, EpiPen will...read more